FXR Stimulation by Obeticholic Acid Treatment Restores Gut Mucosa Functional and Structural Integrity in Individuals With Altered Glucose Tolerance
The intestinal farnesoid X receptor (FXR)/fibroblast growth factor 19 (FGF19) axis is involved in maintaining glucose homeostasis and gut barrier function in animals. Do individuals with prediabetes and type 2 diabetes exhibit a compromised intestinal FXR/FGF19/barrier integrity axis? Can obeticholic acid (OCA) treatment counteract diabetes-related gut mucosa dysfunction? A downregulation of ileal FXR/FGF19/tight-junctions signaling occurs in individuals with hyperglycemia. OCA-mediated FXR activation reverts diabetes-related alterations. OCA-mediated intestinal FXR activation in individuals with hyperglycemia may represent a strategy for restoring FGF19 synthesis with positive effects on gut barrier.
Authors
- R. Marasco (ORCID: https://orcid.org/0000-0001-6918-8169)
- Antonio Facciolo
- Francesco Andreozzi (ORCID: https://orcid.org/0000-0001-9375-1513)
- Teresa Vanessa Fiorentino (ORCID: https://orcid.org/0000-0001-9485-8793)
- Francesco Luzza (ORCID: https://orcid.org/0000-0001-5120-1046)
- Evelina Suraci (ORCID: https://orcid.org/0000-0001-7880-762X)
- Giorgio Sesti (ORCID: https://orcid.org/0000-0002-1618-7688)
- Marta Letizia Hribal (ORCID: https://orcid.org/0000-0001-5932-0541)
- Francesca De Vito
Institutions
- Magna Graecia University (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Diabetes
- Published
- 2025-06-17
- DOI
- https://doi.org/10.2337/db25-0035
- Citations
- 2
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- Fondazione Diabete Ricerca
- European Foundation for the Study of Diabetes
- Società Italiana di Medicina Interna
- Ministero dell'Università e della Ricerca